Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under study in clinical trials. The gene discussed is F3; the disease is hepatocellular carcinoma.